Audit: QRS - Chemical Peel for Skin Rejuvenation
Audit conducted on 11/09/2026 09:20 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | All protocol values (glycolic 20–70%/2–5 min, Jessner’s + 35% TCA, phenol 88% + croton oil 0.1–0.8%), time-to-effect windows, all 10 biomarker targets, cadence, benefits, risks, gates and qualitative markers trace to ER lines 385–399, 446, 416, 476–498, 154–216, 238–308, 328–361. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Cautious ER phrasing is carried where it survives condensation; the HSV serostatus row keeps the ER’s “No established target value; serostatus and prophylaxis adherence are tracked instead” verbatim (ER line 489). |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Pregnancy/breastfeeding stays a contraindication, not a caution; isotretinoin stays depth-qualified as in ER line 352; no tier or gate was moved. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Gates draw only from Key Interactions & Contraindications; benefits from Expected Benefits; risks from Potential Risks & Side Effects. No Benefit- or Risk-Modifying Factor (ER lines 221–231, 313–323) leaks into any card. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT IDs or brand names present. Eponymous terms (“Jessner’s”, “Fitzpatrick”, “Glogau”, “Child-Pugh”) are named scales/solutions used identically in the ER. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions of any kind appear in the QRS. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Neutral, depth-centred framing mirrors the ER’s own “depth decides everything” logic. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Quantified targets and depth tiers throughout; the lede sets expectation without discouraging. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Items are stated as facts and ranges, not orders. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No “should”, “must” or dosing instruction directed at a reader. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Cadence and protocol cells are descriptive/passive (“Applied segmentally under sedation”), echoing ER lines 391–399 and 476. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronoun occurs anywhere in the file. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms retained are those the ER’s own section headings use; the lede substitutes plain equivalents (“precancerous sun spots”, “brown patches”). |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every card is reduced to noun-phrase items; no prose beyond the 58-word lede and the cadence line. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed — no “you”/”your” anywhere in the document. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Content assumes willingness to screen ECG/eGFR/HbA1c and to run a multi-month series. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Qualitative markers explicitly weigh downtime against change achieved. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Monitoring panel and phenol gating are far beyond general-population framing. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | The lede names the modest wrinkle signal alongside the stronger pigment and precancerous-lesion signal, matching ER line 522. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | The string “anti-aging” does not occur in the document. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | Route and agent terms are formal throughout (“oral isotretinoin”, “topical retinoids”, “sedation”, “co-oximetry”); the lede’s plain nouns are the ER’s own conclusion wording. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All present byte-identical to [qrs_template] (lines 437, 474, 516, 536, 542, 553, 572, 576–578, 603). |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | Set comparison against the template returns no missing variable; the repeatable marker_#_* and qualitative_item_# families are expanded to marker_1..10_* and qualitative_item_1..6. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | website="evidence_review", website="audit" and website="full_review" are untouched, as are all CSS, the override stylesheet link and the footer disclaimer. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No ER section feeding the QRS is empty — Protocol, Benefits, Risks, Interactions/Contraindications and Monitoring are all fully populated. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol cell labels are the ER’s bold labels verbatim: “Superficial glycolic acid peel”, “Medium-depth combination peel”, “Deep phenol-croton oil peel” (ER lines 385, 389, 391). |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Biomarker names and tier labels are copied from the ER table (lines 480–489); the time-to-effect labels use the ER’s own depth terms from line 446. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji code points occur in the file; the ER’s “⚠️ Conflicted” markers were correctly dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every card is compressed to the minimum the mandatory-coverage items (8.2, 9.2, 14.2, 15.2) permit; no section carries prose that could be cut without dropping required content. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14; nothing precedes it but the doctype on line 1. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- on line 3, closing --- on line 13; the caption text sits on line 2. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no element mirrors the values. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:03" is quoted, correctly, because it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: chemical_peel_skin_2026-0911-0557_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: 26.7.02, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: 2026-0911-0915. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | Single word, no version. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version, no qualifier such as “(1M context)”. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9 matches the on-disk filename exactly. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys; no stray whitespace or redundant quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Chemical Peel for Skin Rejuvenation - Quick Reference Sheet”; no characters require entity encoding. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: “Chemical Peel for Skin Rejuvenation”, matching ER frontmatter line 8. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: 09/11/2026, the correct reformatting of 2026-0911. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: Opus 5. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header block (lines 415–428) is the template’s structure with only the two variables filled; the ER’s long “Also known as” list was correctly not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses ER line 522 — depth as the governing variable, the shallow-versus-deep trade, and where the evidence is strongest. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 58 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Controlled destruction and regrowth (ER 522/37); shallow clearing roughness, brown patches, acne marks in days (522); deep reshaping for a decade at weeks of recovery with permanent colour change (522/416); pigment and precancerous sun spots strongest, wrinkles modest (522). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; “actinic keratoses” rendered as “precancerous sun spots”, “melasma” as “brown patches”, “post-inflammatory hyperpigmentation” as “acne marks”. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial, author, year or sample size appears. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numeric effect estimate; only the qualitative “modest”. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All 11 items map to ER lines 328/334 and the “Populations who should avoid Chemical Peel” list at lines 352–361. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All 10 avoid-list bullets are carried, plus the QT-prolonging medication bullet the ER marks “Absolute contraindication for phenol peels” (line 334). |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Lines 572–582: eleven discrete <li> elements inside the span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s explanatory gloss on Fitzpatrick phototype (“the darkest two grades on a six-point scale…”, line 355) is stripped; no item carries rationale, citation or a trailing dash clause. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Preserved throughout: “6 months”, “(medium-depth and deep peels)”, “QT interval above 470 ms”, “Child-Pugh Class B or C”, “below 60 mL/min/1.73 m²”, “(glycated hemoglobin above 8%)”, “(phenol peels)”, “beyond very superficial alpha-hydroxy acid”. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in its contraindication list. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The section is populated, as required — the ER names ten such populations plus two absolute contraindications. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All nine items map one-to-one to ER bullets at lines 330–348. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | The ER’s eleven interaction bullets minus the two absolute contraindications (oral isotretinoin, QT-prolonging medication) yield exactly the nine items listed. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Lines 590–598: nine discrete <li> elements inside the span. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Mechanism and mitigation sentences from ER lines 330–348 are stripped; no citations, no trailing dash clauses. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Named examples preserved: “(tretinoin, adapalene, tazarotene)”, “(doxycycline, ciprofloxacin, hydrochlorothiazide, amiodarone)”, “(aspirin, salicylate rubs, acne washes)”, “(St John’s wort, high-dose niacin, bergamot or citrus essential oils)”, “(fish oil, high-dose vitamin E, ginkgo, garlic extract)”, “(oral tranexamic acid, Polypodium leucotomos)”, “(microneedling, fractional laser, photodynamic therapy)”, plus “(additive benefit)”. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in its interaction bullets. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The section is populated, as required — the ER names nine non-contraindication interactions. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells derive from ER Therapeutic Protocol lines 385, 389, 391 and 399. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | One protocol per depth tier — superficial glycolic, medium-depth Jessner’s + TCA, deep phenol-croton oil — which is the axis the ER identifies as governing the whole intervention. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER names four distinct protocols; all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine spans carry ER-sourced content: concentrations, contact times, neutralization, session spacing, the Monheit standard plus the Coleman and Brody alternatives, and segmental phenol application at 10–15 minute intervals. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | The ER’s Time to effect bullet (line 446) names exactly three windows — deep, medium, superficial — and all three are carried. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Deep → medium → superficial, matching the ER’s depth-equals-magnitude logic (lines 424, 450, 522). |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct aspects exist; all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine spans populated; the deep-peel sub-line adds the ER’s own durability statement “results reported to persist a decade or longer” (line 416). |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect data at line 446, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All ten items correspond to the ER’s ten benefit headings (lines 156–216). |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present and populated at lines 541–562. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each item is the ER heading reduced to a noun phrase; every Magnitude: line (4.34%, MASI −1.89, RR 2.30, 12–46% clearance) is stripped. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | The ER’s glosses (“rough precancerous sun spots that can progress to…”, “flat brown spots from cumulative light exposure”, “GAGs, water-binding sugars…”) are all removed. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers carry items in the ER, so no span needed hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All eleven items correspond to the ER’s eleven risk headings (lines 240–308). |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present and populated at lines 610–629. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Frequencies (5.9%, 6 of 12, 21%, 25%), the RR 4.42 comparison and the “⚠️ Conflicted” marker on the isotretinoin item are all stripped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | ER glosses (“PIH, brown staining where inflamed skin has healed”, “HSV, the cold-sore virus”, “tiny white keratin cysts”) are removed. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers carry items in the ER, so no span needed hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Rows and cadence come from the ER Monitoring Protocol & Defining Success section, lines 476–489. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All 10 ER table rows are present in order, with Target and Why columns copied verbatim (Fitzpatrick phototype, Glogau grade, ECG/QTc, creatinine/eGFR, ALT/AST, HbA1c, methemoglobin, serum salicylate, 25-hydroxyvitamin D, HSV IgG). |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Lines 779–783 carry the full ER schedule — 48–72 h, 2 weeks, 6–8 weeks, 3 and 6 months, then every 6–12 months — plus the phenol-only laboratory repeat at 24 hours (ER line 476). |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Items come from the ER’s “Qualitative markers that define whether the result is worth the cost” list, lines 493–498. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six ER bullets are present, in order and essentially verbatim, at lines 791–824. |
Issues 11/09/2026 09:20
Pass rate 100.00%. No issues found.